Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of orally administered Fx-1006A in patients with familial amyloid polyneuropathy (FAP): A randomized, double-blind, placebo-controlled study.

Trial Profile

Safety and efficacy of orally administered Fx-1006A in patients with familial amyloid polyneuropathy (FAP): A randomized, double-blind, placebo-controlled study.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Aug 2016 According to a Pfizer media release, results of pooled post hoc analysis from this and other two trials (Profiles 275556 and 252196) were published online in Amyloid: The Journal of Protein Folding Disorders.
    • 08 Aug 2016 Results of pooled post hoc analysis from this and other two trials (Profiles 275556 and 252196) published in a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top